insulin glargine vs Insulin glargine (Basaglar)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
insulin glargine · Lantus
Marketed by Sanofi
NCT00069784 · Phase 3 · completed
The trial randomized 12,537 participants and used adjudicated clinical cardiovascular events, but treatment assignment was open-label rather than double-blinded. Neither primary cardiovascular endpoint was statistically significant in favor of insulin glargine, so the evidence supports a well-powered but inconclusive or negative finding rather than strong evidence of benefit.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
No aligned efficacy figure on record for this race.
Insulin glargine (Basaglar)
Marketed by Eli Lilly and partners
NCT01421459 · Phase 3 · completed
The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) (met)
Result source: NCT03338010
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin glargine | Insulin glargine (Basaglar) |
|---|---|---|
| HbA1c, change | -0.6% vs -0.8%vs Insulin IcodecNCT0634085418 other results
| -1.3% vs -1.3%vs LantusNCT014214599 other results
|
| Body weight, change (kg) | 0.6 vs 2.0vs Insulin IcodecNCT063408547 other results
| 1.9 vs 2.2vs LantusNCT014214597 other results
|
| HbA1c below 7% | 48.4% vs 45.9%vs LiraglutideNCT011173504 other results
| 43.7% vs 44.9%vs Lantus®NCT03338010 |
| Fasting plasma glucose, change | -3.6 vs -2.1vs LiraglutideNCT011173504 other results
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT00044447 | —Not reported |
HbA1c, change
- insulin glargine
- -0.6% vs -0.8%vs Insulin IcodecNCT06340854
18 other results
- -1.0% vs -1% NCT05462756
- -1.0% vs -1% NCT05462756
- -1.7% vs -1.1% NCT00751114
- -1.7% vs -1.4% NCT00391027
- -2.0% vs -1.8% NCT00418522
- -1.3% vs -1.4% NCT00686712
- -1.9% vs -1.4% NCT00686712
- -1.3% vs -1.4% NCT02455076
- -1.1% vs -1.4% NCT02455076
- -1.9% vs -1.8% NCT01117350
- -1.9% vs -1.7% NCT00418522
- -0.4% vs -0.1% NCT00360698
- -1.7% vs -1.5% NCT00391027
- -1.6% vs -1.3% NCT00391027
- -1.3% vs -1.1% NCT00391027
- -0.8% vs -0.6% NCT00391027
- -0.4% vs -0.3% NCT00391027
- -2.5% vs -2.1% NCT00384085
- Insulin glargine (Basaglar)
- -1.3% vs -1.3%vs LantusNCT01421459
9 other results
- -1.3% vs -1.2% NCT02302716
- -1.3% vs -1.2% NCT03338010
- -1.3% vs -1.4% NCT01421459
- -1.3% vs -1.2% NCT03338010
- -1.3% vs -1.4% NCT01421459
- -1.3% vs -1.3% NCT01421459
- -1.1% vs -1.1% NCT01421459
- -0.9% vs -0.9% NCT01421459
- -0.5% vs -0.5% NCT01421459
Body weight, change (kg)
- insulin glargine
- 0.6 vs 2.0vs Insulin IcodecNCT06340854
7 other results
- 2.7 vs 2.5 NCT05462756
- 2.0 vs -3.0 NCT01117350
- 0.4 vs -1.1 NCT00751114
- 3.5 vs 2.3 NCT00418522
- 0.5 vs 0.2 NCT00360698
- 2.2 vs 1.1 NCT00391027
- -1 vs -0.5 NCT02455076
- Insulin glargine (Basaglar)
- 1.9 vs 2.2vs LantusNCT01421459
7 other results
- 2.3 vs 1.7 NCT02302716
- 1.1 vs 1.2 NCT03338010
- 1.7 vs 2.2 NCT01421459
- 1.6 vs 1.9 NCT01421459
- 1.3 vs 1.4 NCT01421459
- 1.0 vs 1.2 NCT01421459
- 0.3 vs 0.5 NCT01421459
HbA1c below 7%
- insulin glargine
- 48.4% vs 45.9%vs LiraglutideNCT01117350
4 other results
- 22.4% vs 8.8% NCT00360698
- 67.9% vs 41.9% NCT00751114
- 62.6% vs 47.6% NCT00418522
- 51.1% vs 39.5% NCT00384085
- Insulin glargine (Basaglar)
- 43.7% vs 44.9%vs Lantus®NCT03338010
Fasting plasma glucose, change
- insulin glargine
- -3.6 vs -2.1vs LiraglutideNCT01117350
4 other results
- -1.7 vs -3.3 NCT00391027
- -2.9 vs -3.0 NCT00418522
- -3.4 vs -1.1 NCT00751114
- -0.8 vs -0.8 NCT01226043
- Insulin glargine (Basaglar)
- —Not reported
3-point MACE (% with event)
- insulin glargine
- —Not posted · NCT00044447
- Insulin glargine (Basaglar)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. insulin glargine: 7 of 7 rows · Insulin glargine (Basaglar): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin glargine Rows use multiple source trials | Insulin glargine (Basaglar) Rows use multiple source trials |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.86% (n=259) @ 24wka,b NCT04153981 · Phase 4 · registry result, not featured evidence | -0.86% (n=259) @ 24wka,b NCT04153981 · Phase 4 · registry result, not featured evidence |
| SMBG 7-point Change mg/dL absolute change · mg No placebo or comparator arm Blood glucose concentration before breakfast | -38.7 mg @ 24wka,b Blood glucose concentration before breakfast NCT04153981 · Phase 4 · registry result, not featured evidence | -38.7 mg @ 24wka,b Blood glucose concentration before breakfast NCT04153981 · Phase 4 · registry result, not featured evidence |
| Weight absolute change · kg No placebo or comparator arm | -0.5 kg @ 24wka,b NCT04153981 · Phase 4 · registry result, not featured evidence | -0.5 kg @ 24wka,b NCT04153981 · Phase 4 · registry result, not featured evidence |
| Dropout rate | 19.3%c NCT00069784 · Phase 3 show 29 more results11.3% NCT05114590 · Phase 4 · registry result, not featured evidence 28.3% NCT04153981 · Phase 4 · registry result, not featured evidence 1.3% NCT02561130 · Phase 4 · registry result, not featured evidence 8.5%Exenatide Inpatient NCT02455076 · Phase 4 · registry result, not featured evidence —Exenatide Outpatient NCT02455076 · Phase 4 · registry result, not featured evidence 2%Exenatide Plus Glargine Insulin In NCT02455076 · Phase 4 · registry result, not featured evidence · combination —Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence —Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 8.6%Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence —Crossover Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Observational Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Re-randomization Phase: SoloSTAR® NCT01226043 · Phase 4 · registry result, not featured evidence —SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 15.2% NCT00751114 · Phase 4 · registry result, not featured evidence 12.3%0.5 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 0%0.25 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 23.5%Lantus/Apidra-1 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 20%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 33.3%Insulin Glargine at Bedtime NCT00686712 · Phase 4 · registry result, not featured evidence 44%Insulin Glargine in AM NCT00686712 · Phase 4 · registry result, not featured evidence — NCT00360698 · Phase 4 · registry result, not featured evidence · combination 18.5% NCT00391027 · Phase 4 · registry result, not featured evidence 37.9% NCT00418522 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination 1.5% NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 9.3%Insulin Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 4.7% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 | 11.9%d NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results7.6% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.4% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 28.3% NCT04153981 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 1.7%c NCT00069784 · Phase 3 show 29 more results0.8% NCT05114590 · Phase 4 · registry result, not featured evidence — NCT04153981 · Phase 4 · registry result, not featured evidence — NCT02561130 · Phase 4 · registry result, not featured evidence 6.4%Exenatide Inpatient NCT02455076 · Phase 4 · registry result, not featured evidence —Exenatide Outpatient NCT02455076 · Phase 4 · registry result, not featured evidence 0%Exenatide Plus Glargine Insulin In NCT02455076 · Phase 4 · registry result, not featured evidence · combination —Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence —Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 1.2%Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence —Crossover Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Observational Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Re-randomization Phase: SoloSTAR® NCT01226043 · Phase 4 · registry result, not featured evidence —SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 0.8% NCT00751114 · Phase 4 · registry result, not featured evidence —0.5 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence —0.25 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 2.6%Lantus/Apidra-1 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 2.6%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 3.3%Insulin Glargine at Bedtime NCT00686712 · Phase 4 · registry result, not featured evidence 4%Insulin Glargine in AM NCT00686712 · Phase 4 · registry result, not featured evidence — NCT00360698 · Phase 4 · registry result, not featured evidence · combination 5.9% NCT00391027 · Phase 4 · registry result, not featured evidence 3.2% NCT00418522 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination — NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Insulin Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 0.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 | 1.6%d NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results0.4% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.8% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT04153981 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 4.9%c NCT00069784 · Phase 3 show 29 more results0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence 3.9% NCT02561130 · Phase 4 · registry result, not featured evidence 14.9%Exenatide Inpatient NCT02455076 · Phase 4 · registry result, not featured evidence 22.9%Exenatide Outpatient NCT02455076 · Phase 4 · registry result, not featured evidence 23.5%Exenatide Plus Glargine Insulin In NCT02455076 · Phase 4 · registry result, not featured evidence · combination 2.3%Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence 3.1%Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence —Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 1%Crossover Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 10.1%Observational Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 0.6%Re-randomization Phase: SoloSTAR® NCT01226043 · Phase 4 · registry result, not featured evidence —SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 6.3% NCT00751114 · Phase 4 · registry result, not featured evidence 0%0.5 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 0%0.25 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 11.9%Lantus/Apidra-1 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 11.3%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 0%Insulin Glargine at Bedtime NCT00686712 · Phase 4 · registry result, not featured evidence 4%Insulin Glargine in AM NCT00686712 · Phase 4 · registry result, not featured evidence 2% NCT00360698 · Phase 4 · registry result, not featured evidence · combination 5.9% NCT00391027 · Phase 4 · registry result, not featured evidence — NCT00418522 · Phase 4 · registry result, not featured evidence 0% NCT00467649 · Phase 4 · registry result, not featured evidence · combination 5.8% NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 6.5%Efsitora NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 5.3%Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Insulin Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 6.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 | 4%d NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results4% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.8% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | c hypoglycaemia 5.7% upper respiratory tract infection 5.7% NCT05114590 · Phase 4 · registry result, not featured evidence show 22 more resultsanaemia 1.9% cough 0.4% hyperglycaemia 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence genitourinary infection 5.2% abdominal pain 3.9% injury 3.9% NCT02561130 · Phase 4 · registry result, not featured evidence nausea 9.8% vomiting 5.9% NCT02455076 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 7.9% headache 5% diarrhoea 3.7% NCT01117350 · Phase 4 · registry result, not featured evidence nasopharyngitis 7.5% diarrhoea 3.1% headache 1.3% NCT01117350 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 1.8% nasopharyngitis 1.3% sinusitis 1% NCT01226043 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 8.8% sinusitis 7.5% oedema peripheral 5% NCT01226043 · Phase 4 · registry result, not featured evidence nasopharyngitis 3.6% upper respiratory tract infection 2.4% sinusitis 1.2% NCT01226043 · Phase 4 · registry result, not featured evidence headache 6.3% influenza 3.4% nasopharyngitis 3.4% NCT00751114 · Phase 4 · registry result, not featured evidence any infections and infestations 42.3% any musculoskeletal and connective tissue disorders 22.7% any gastrointestinal disorders 16.5% NCT00384085 · Phase 4 · registry result, not featured evidence · combination any infections and infestations 34% any musculoskeletal and connective tissue disorders 23.2% any nervous system disorders 20.1% NCT00384085 · Phase 4 · registry result, not featured evidence · combination symptomatic hypoglycemia 76.7% asymptomatic retinal hemorrhage 3.3% urinary tract infection 0% NCT00686712 · Phase 4 · registry result, not featured evidence symptomatic hypoglycemia 96% asymptomatic retinal hemorrhage 0% urinary tract infection 0% NCT00686712 · Phase 4 · registry result, not featured evidence hypoglycaemia 70.4% nasopharyngitis 13.3% cough 6.7% NCT00391027 · Phase 4 · registry result, not featured evidence hypoglycaemia 67.9% tremor 31.6% dizziness 18.9% NCT00418522 · Phase 4 · registry result, not featured evidence nausea 11.1% diarrhoea 5.6% hypertension 5.6% NCT00467649 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 7.8% diabetic retinopathy 7.3% diarrhoea 1.9% NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 influenza 7.3% covid-19 5.3% hypertension 5.3% NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 drug titration error 9.8% urinary tract infection 6.3% influenza 5.8% NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 nasopharyngitis 6.3% influenza 3.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 | d nasopharyngitis 5.6% upper respiratory tract infection 5.1% abnormal weight gain 2.7% NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more resultsnasopharyngitis 7.2% upper respiratory tract infection 4% weight increased 3.2% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 upper respiratory tract infection 20.3% hypertension 5.6% injection site pain 4.2% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 anaemia 1.9% cough 0.4% hyperglycaemia 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cPopulation comparability has not been reviewed for 25 of these studies.
- dPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin glargine
show 1 more result
+ 60 further endpoints in the CSV export.
Insulin glargine (Basaglar)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin glargine's landscape · Insulin glargine (Basaglar)'s landscape